Diamyd Medical AB
- Country
- 🇸🇪Sweden
- Ownership
- Public
- Established
- 1994-01-01
- Employees
- 25
- Market Cap
- -
- Website
- http://www.diamyd.com
Clinical Trials
19
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals At Risk for Type 1 Diabetes
- Conditions
- Diabetes Mellitus, Type 1PreventionAutoimmune Diseases
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Diamyd Medical AB
- Target Recruit Count
- 16
- Registration Number
- NCT05683990
- Locations
- 🇸🇪
Lund University/CRC, Skåne University Hospital,, Malmö, Sweden
A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Biological: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®Dietary Supplement: Colecalciferol 2000 IUBiological: Placebo
- First Posted Date
- 2021-08-24
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Diamyd Medical AB
- Target Recruit Count
- 330
- Registration Number
- NCT05018585
- Locations
- 🇺🇸
Mary and Dick Allen Diabetes Center at Hoag Hospital, Newport Beach, California, United States
🇺🇸Stanford University School of Medicine Center for Academic Medicine, Palo Alto, California, United States
🇺🇸UCSD/ Rady Children's Hospital, San Diego, California, United States
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
- Conditions
- Metabolic DiseaseInsulin Dependent DiabetesDiabetes MellitusEndocrine System DiseasesJuvenile DiabetesAutoimmune DiabetesVitamin DPhysiological Effects of DrugsAutoimmune DiseasesDiabetes Mellitus, Type 1
- First Posted Date
- 2017-11-17
- Last Posted Date
- 2023-01-09
- Lead Sponsor
- Diamyd Medical AB
- Target Recruit Count
- 109
- Registration Number
- NCT03345004
- Locations
- 🇨🇿
Diabetes Centre, Institute of Clinical and Experimental Medicine, Praha, Czechia
🇨🇿Department of Paediatrics, University Hospital Motol, Praha, Czechia
🇳🇱Diabeter Rotterdam, Rotterdam, Netherlands
News
Diamyd Medical's DIAGNODE-3 Trial Exceeds Recruitment Target for Early Readout
Diamyd Medical's DIAGNODE-3 trial, a Phase 3 precision medicine study, has recruited 180 patients, surpassing the target for its planned early readout in March 2026.